Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALAN SR vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Essential hypertension,Chronic stable angina,Variant (Prinzmetal) angina,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT),Off-label: migraine prophylaxis, cluster headache,Off-label: hypertrophic cardiomyopathy
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Oral: 180–240 mg once daily; maximum 480 mg/day.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life is 6-12 hours (average ~8 hours) after single oral dose; may increase to 12-16 hours with chronic dosing due to saturable hepatic metabolism; clinical context: requires dosing adjustments in hepatic impairment.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Primarily hepatic via CYP3A4; first-pass metabolism; major metabolite norverapamil retains 20% activity.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Approximately 70% of the dose is excreted as metabolites in the urine; 3-4% as unchanged drug; 25% eliminated in feces via biliary excretion.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Approximately 90% bound to plasma proteins (mainly albumin).
92-98% bound to plasma proteins (primarily albumin)
3.5 L/kg; indicates extensive tissue binding and distribution beyond plasma volume.
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral (sustained-release): 40-60% due to first-pass metabolism; immediate-release: 70-80% when fasting but reduced to ~50% with food.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
Cr Cl <30 m L/min: reduce dose by 50–75% of normal; initiate at lower end of dosing range.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh A: no adjustment; Child-Pugh B or C: reduce dose by 50% and monitor.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not FDA-approved for children; limited data: 4–8 mg/kg/day divided twice daily (immediate-release form only).
Not recommended for use in pediatric patients; safety and efficacy not established.
Initiate at 120 mg once daily; titrate slowly due to increased bioavailability and prolonged half-life.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
None
No FDA black box warning.
Heart failure: may exacerbate due to negative inotropic effects,Hypotension,Bradycardia/AV block: avoid in sick sinus syndrome or high-grade AV block without pacemaker,Hepatic impairment: reduce dose,Concomitant beta-blockers: increased risk of bradycardia and heart failure,Digoxin toxicity: verapamil increases digoxin levels
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Severe left ventricular dysfunction (ejection fraction <30%),Cardiogenic shock,Sick sinus syndrome or 2nd/3rd degree AV block (except with functioning pacemaker),Atrial fibrillation/flutter with accessory bypass tract (e.g., WPW),Hypersensitivity to verapamil
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Avoid grapefruit and grapefruit juice as they can increase verapamil levels. Limit alcohol consumption as it may enhance hypotensive effects. High-fat meals may delay absorption but not significantly affect overall bioavailability.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
Verapamil (CALAN SR) is classified as FDA Pregnancy Category C. First trimester: Animal studies have shown embryotoxicity and fetotoxicity, but no well-controlled human studies exist. Risk cannot be ruled out. Second/third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion. Avoid use in pregnancy unless benefit outweighs risk.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Verapamil is excreted into breast milk with a milk-to-plasma ratio (M/P) of approximately 0.23 to 0.94 (mean~0.6). Infant dose is low (<5% maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Consider monitoring infant for bradycardia, hypotension, and constipation.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
Pregnancy may increase verapamil clearance due to expanded plasma volume and enhanced renal/hepatic metabolism. Dose adjustments may be needed to maintain therapeutic effect; monitor clinical response and consider therapeutic drug monitoring. Start at lower doses and titrate cautiously.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
CALAN SR (verapamil sustained-release) is a non-dihydropyridine calcium channel blocker used for hypertension and angina. Avoid use in patients with pre-existing severe left ventricular dysfunction, hypotension, or sick sinus syndrome without a pacemaker. Caution with concomitant beta-blockers due to risk of bradycardia or heart block. Verapamil is a potent CYP3A4 inhibitor; monitor for increased levels of statins, cyclosporine, and other CYP3A4 substrates.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take exactly as prescribed; do not crush or chew the extended-release tablet.,Can be taken with or without food, but avoid grapefruit and grapefruit juice.,Do not suddenly stop taking this medication; abrupt withdrawal may worsen chest pain.,Report symptoms of heart failure such as shortness of breath, swelling of ankles/feet.,May cause dizziness or fatigue; avoid driving until you know how it affects you.,Constipation is common; maintain adequate fluid and fiber intake.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALAN SR vs AFEDITAB CR, answered by our medical review team.
CALAN SR is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALAN SR and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALAN SR is: Oral: 180–240 mg once daily; maximum 480 mg/day.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALAN SR and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALAN SR is classified as Category C. Verapamil (CALAN SR) is classified as FDA Pregnancy Category C. First trimester: Animal studies have shown embryotoxicity and fetotoxicity, but no well-controlled human studies exi. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.